# QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

> **NCT03387085** · PHASE1,PHASE2 · TERMINATED · sponsor: **ImmunityBio, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Aldoxorubicin HCl
- **BIOLOGICAL:** N-803
- **BIOLOGICAL:** ETBX-011
- **BIOLOGICAL:** ETBX-051
- **BIOLOGICAL:** ETBX-061
- **BIOLOGICAL:** GI-4000
- **BIOLOGICAL:** GI-6207
- **BIOLOGICAL:** GI-6301
- **BIOLOGICAL:** haNK for Infusion
- **BIOLOGICAL:** avelumab
- **BIOLOGICAL:** bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin
- **DRUG:** Cyclophosphamide
- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** nab-Paclitaxel
- **PROCEDURE:** SBRT

## Key facts

- **NCT ID:** NCT03387085
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-19
- **Primary completion:** 2020-09-11
- **Final completion:** 2024-01-16
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03387085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03387085, "QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03387085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*